Registry of Treatment Outcomes in a Non-study Population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223
Condition: Prostate Cancer Metastatic, Bone Metastases
Study Type: Observational
Clinical Trials Identifier NCT 8-digits: NCT03223727
Sponsor: The Netherlands Cancer Institute
- Age: minimum 18 Years maximum N/A
- Gender: Male
- At the physicians discretion
- Age 18 year and older.
- Written informed consent
- Previous treatment with Radium-223.
- Participation in another Radium-223 study.
View trial on ClinicalTrials.gov